Literature DB >> 19250446

Dermatologic conditions seen in end-stage renal disease.

Katharine B Cordova1, Thomas J Oberg, Mohsin Malik, Leslie Robinson-Bostom.   

Abstract

The skin changes reported in patients with end-stage renal disease (ESRD) are diverse and manifold. In this article we focus on a collection of specific cutaneous entities seen most frequently in the setting of ESRD, each presenting with distinctive and unique morphology. These include perforating disorders, porphyria cutanea tarda, pseudoporphyria, calcinosis cutis, calciphylaxis, and nephrogenic systemic fibrosis. The clinical features, histopathology, pathophysiology, differential diagnosis, and management of each entity are reviewed.

Entities:  

Mesh:

Year:  2009        PMID: 19250446     DOI: 10.1111/j.1525-139X.2008.00534.x

Source DB:  PubMed          Journal:  Semin Dial        ISSN: 0894-0959            Impact factor:   3.455


  5 in total

1.  Secondary hyperparathyroidism: Uncommon cause of a leg ulcer.

Authors:  L B van Rijssen; E E A Brenninkmeijer; E J M Nieveen van Dijkum
Journal:  Int J Surg Case Rep       Date:  2011-10-28

2.  IL-6/p-BTK/p-ERK signaling mediates calcium phosphate-induced pruritus.

Authors:  Sunita Keshari; Chien-Lung Chen; Apriska Dewi Sipayung; Ching-Chuan Hsieh; Li-Jen Su; Yun-Ru Chiang; Huan-Cheng Chang; Wu-Chang Yang; Tsung-Hsien Chuang; Chun-Ming Huang
Journal:  FASEB J       Date:  2019-07-31       Impact factor: 5.191

3.  Pseudoporphyria in a haemodialysis patient.

Authors:  Cheng-Chia Lee; Ja-Liang Lin; Hsiang-Hung Hsieh; Tzung-Hai Yen
Journal:  NDT Plus       Date:  2010-08-24

4.  Renal Transplantation Could Reverse Dialysis-Associated Porphyria.

Authors:  Sasanka K Barua; Sachinkumar Patel; Debanga Sarma; Mandeep Phukan; Puskal K Bagchi
Journal:  Cureus       Date:  2022-08-27

5.  Inflammatory Cutaneous Diseases in Renal Transplant Recipients.

Authors:  Paola Savoia; Giovanni Cavaliere; Elisa Zavattaro; Federica Veronese; Paolo Fava
Journal:  Int J Mol Sci       Date:  2016-08-19       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.